8XZH image
Entry Detail
PDB ID:
8XZH
EMDB ID:
Title:
Cryo-EM structure of the MM07-bound human APLNR-Gi complex
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2024-01-21
Release Date:
2024-03-20
Method Details:
Experimental Method:
Resolution:
2.60 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(i) subunit alpha-1
Chain IDs:B (auth: A)
Chain Length:354
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:C (auth: B)
Chain Length:339
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Chain IDs:D (auth: G)
Chain Length:71
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:MM07
Chain IDs:F (auth: L)
Chain Length:13
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polypeptide(L)
Description:Apelin receptor
Chain IDs:A (auth: R)
Chain Length:380
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:scFv16
Chain IDs:E (auth: S)
Chain Length:256
Number of Molecules:1
Biological Source:synthetic construct
Ligand Molecules
Primary Citation
Structure-based design of non-hypertrophic apelin receptor modulator.
Cell 187 1460 1475.e20 (2024)
PMID: 38428423 DOI: 10.1016/j.cell.2024.02.004

Abstact

Apelin is a key hormone in cardiovascular homeostasis that activates the apelin receptor (APLNR), which is regarded as a promising therapeutic target for cardiovascular disease. However, adverse effects through the β-arrestin pathway limit its pharmacological use. Here, we report cryoelectron microscopy (cryo-EM) structures of APLNR-Gi1 complexes bound to three agonists with divergent signaling profiles. Combined with functional assays, we have identified "twin hotspots" in APLNR as key determinants for signaling bias, guiding the rational design of two exclusive G-protein-biased agonists WN353 and WN561. Cryo-EM structures of WN353- and WN561-stimulated APLNR-G protein complexes further confirm that the designed ligands adopt the desired poses. Pathophysiological experiments have provided evidence that WN561 demonstrates superior therapeutic effects against cardiac hypertrophy and reduced adverse effects compared with the established APLNR agonists. In summary, our designed APLNR modulator may facilitate the development of next-generation cardiovascular medications.

Legend

Protein

Chemical

Disease

Primary Citation of related structures